Cargando…

Trends of clinical symptoms and prognosis of middle-aged prostate cancer patients after instigation of prostate specific antigen-based population screening

PURPOSE: Due to the low rate of screening for prostate cancer in Japan, the incidence rates of cancer are high. We have established a prostate-specific antigen (PSA)-based screening system for prostate cancer in our region. We analyzed recent trends of clinical symptoms and prognosis of prostate can...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kitagawa, Yasuhide, Mizokami, Atsushi, Namiki, Mikio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Asian Pacific Prostate Society (APPS) 2013
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3814114/ https://www.ncbi.nlm.nih.gov/pubmed/24223404 http://dx.doi.org/10.12954/PI.12017

Ejemplares similares

Decreasing trend in prostate cancer with high serum prostate-specific antigen levels detected at first prostate-specific antigen-based population screening in Japan
por: Kitagawa, Yasuhide, et al.
Publicado: (2014)

Prostate-specific antigen-based population screening for prostate cancer: current status in Japan and future perspective in Asia
por: Kitagawa, Yasuhide, et al.
Publicado: (2015)

Understanding prostate-specific antigen dynamics in monitoring metastatic castration-resistant prostate cancer: implications for clinical practice
por: Mizokami, Atsushi, et al.
Publicado: (2017)

An Unusual Prostate-Specific Antigen Decrease in an Advanced Castration-Resistant Prostate Cancer Patient with Intracerebral Hemorrhage Subsequently Treated with Luteinizing Hormone-Releasing Hormone Antagonist
por: Izumi, Kouji, et al.
Publicado: (2013)

Prognosis of patients with prostate cancer and middle range prostate - specific antigen levels of 20 – 100 ng / mL
por: Iwamoto, Hiroaki, et al.
Publicado: (2019)

Role of hormonal therapy for prostate cancer: perspective from Japanese experiences
por: Namiki, Mikio, et al.
Publicado: (2012)

Prospective longitudinal comparative study of health-related quality of life and treatment satisfaction in patients treated with hormone therapy, radical retropubic prostatectomy, and high or low dose rate brachytherapy for prostate cancer
por: Miwa, Sotaro, et al.
Publicado: (2013)

Background factors and short-term health-related quality of life in patients who initially underwent radical prostatectomy or androgen deprivation therapy for localized prostate cancer in a Japanese prospective observational study (J-CaP Innovative Study-1)
por: Ueno, Satoru, et al.
Publicado: (2018)

Serum chemokine (CC motif) ligand 2 level as a diagnostic, predictive, and prognostic biomarker for prostate cancer
por: Izumi, Kouji, et al.
Publicado: (2015)

Re: Prognosis of prostate cancer and prostate - specific antigen levels
por: Joob, Beuy, et al.
Publicado: (2019)

Advice About Screening for Prostate Cancer With Prostate-Specific Antigen
por: Jean-Pierre, Gannel
Publicado: (2017)

Metastatic Urothelial Carcinoma of the Prepuce and Glans Penis: Suspected Implantation of Non-Muscle-Invasive Bladder Cancer via Urine
por: Makino, Tomoyuki, et al.
Publicado: (2014)

The Prostate Cancer Detection Rate on the Second Prostate Biopsy according to Prostate-Specific Antigen Trend
por: Kim, Hyung-Sang, et al.
Publicado: (2012)

Bioimpedance and chronoamperometry as an adjunct to prostate-specific antigen screening for prostate cancer
por: de Abreu, Darci Schiavon
Publicado: (2011)

Overdetection, overtreatment and costs in prostate-specific antigen screening for prostate cancer
por: Heijnsdijk, E A M, et al.
Publicado: (2009)

Prostate cancer screening with prostate-specific antigen: A guide to the guidelines
por: Cabarkapa, Sonja, et al.
Publicado: (2016)

Gene‒Prostate-Specific-Antigen-Guided Personalized Screening for Prostate Cancer
por: Yang, Teng-Kai, et al.
Publicado: (2019)

Prostate-Specific Antigen Screening and Recent Increases in Advanced Prostate Cancer
por: Nyame, Yaw A, et al.
Publicado: (2020)

Beyond Prostate Specific Antigen: New Prostate Cancer Screening Options
por: Narain, Tushar Aditya, et al.
Publicado: (2022)

Optimal treatment for castration-resistant prostate cancer
por: Izumi, Kouji, et al.
Publicado: (2014)

Potent Stimulation of the Androgen Receptor Instigates a Viral Mimicry Response in Prostate Cancer
por: Alizadeh-Ghodsi, Mohammadreza, et al.
Publicado: (2022)

Specificity of serum prostate-specific antigen determination in the Finnish prostate cancer screening trial
por: Määttänen, L, et al.
Publicado: (2007)

The neutrophil-to-lymphocyte ratio at the prostate-specific antigen nadir predicts the time to castration-resistant prostate cancer
por: Iwamoto, Genta, et al.
Publicado: (2021)

Targeting the androgen receptor with siRNA promotes prostate cancer metastasis through enhanced macrophage recruitment via CCL2/CCR2-induced STAT3 activation
por: Izumi, Kouji, et al.
Publicado: (2013)

High testosterone levels in prostate tissue obtained by needle biopsy correlate with poor-prognosis factors in prostate cancer patients
por: Miyoshi, Yasuhide, et al.
Publicado: (2014)

Prostate Cancer Detection and Prognosis: From Prostate Specific Antigen (PSA) to Exosomal Biomarkers
por: Filella, Xavier, et al.
Publicado: (2016)

Prostate-specific antigen velocity in diagnosis and prognosis of prostate cancer - a systematic review
por: Javaeed, Arslaan, et al.
Publicado: (2020)

Prostate-Specific Antigen (PSA) Screening and New Biomarkers for Prostate Cancer (PCa)
por: Stephan, Carsten, et al.
Publicado: (2014)

Screening for prostate cancer: a study on the free and total prostate specific antigen
por: Mediu, Ridvana, et al.
Publicado: (2021)

Prostate-specific antigen screening for prostate cancer: An old but never-ending story
por: Kim, Sun Il
Publicado: (2023)

Effect of Obesity on Prostate-Specific Antigen, Prostate Volume, and International Prostate Symptom Score in Patients with Benign Prostatic Hyperplasia
por: Kim, Jong Min, et al.
Publicado: (2011)

Co-expression and impact of prostate specific membrane antigen and prostate specific antigen in prostatic pathologies
por: Ben Jemaa , Awatef, et al.
Publicado: (2010)

Prostate hyperplasia in St Mary's Hospital Lacor: utility of prostate specific antigen in screening for prostate malignancy
por: Okidi, Ronald, et al.
Publicado: (2020)

Prostate-Specific Antigen Nadir and Time to Prostate-Specific Antigen Nadir Following Maximal Androgen Blockade Independently Predict Prognosis in Patients with Metastatic Prostate Cancer
por: Hong, Seok Young, et al.
Publicado: (2012)

Prostate-specific antigen-based screening: controversy and guidelines
por: Kim, Eric H, et al.
Publicado: (2015)

Prostate specific antigen /
Publicado: (2001)

Adding free to total prostate-specific antigen levels in trials of prostate cancer screening
por: Wald, N J, et al.
Publicado: (2000)

Is Prostate-Specific Antigen Effective for Population Screening of Prostate Cancer? A Systematic Review
por: Lee, Yoon Jae, et al.
Publicado: (2013)

Discoveries and application of prostate-specific antigen, and some proposals to optimize prostate cancer screening
por: Tokudome, Shinkan, et al.
Publicado: (2016)

The Value of Prostate-Specific Antigen-Related Indexes and Imaging Screening in the Diagnosis of Prostate Cancer
por: Bai, Xiaojing, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_pe42f83llb9terh7kcpcp2tl6o